$7.21
0.96% day before yesterday
Nasdaq, Dec 24, 07:02 pm CET
ISIN
US98422E1038
Symbol
XERS

Xeris Biopharma Holdings Stock price

$7.21
+0.17 2.41% 1M
+2.55 54.72% 6M
+3.82 112.68% YTD
+3.74 107.78% 1Y
+5.95 472.22% 3Y
+1.76 32.29% 5Y
-13.01 64.34% 10Y
-13.01 64.34% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
-0.07 0.96%
ISIN
US98422E1038
Symbol
XERS
Industry

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
$127.9m
Cash
$91.6m
Shares outstanding
165.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
-9.2%
Return on Equity
185.2%
ROCE
3.9%
ROIC
3.6%
Debt/Equity
-255.2
Financials (TTM | estimate)
Revenue
$266.1m | $293.2m
EBITDA
$20.7m | $54.0m
EBIT
$9.8m | $17.7m
Net Income
$-15.6m | $-7.3m
Free Cash Flow
$10.0m
Growth (TTM | estimate)
Revenue
42.1% | 44.4%
EBITDA
160.2% | 336.7%
EBIT
121.7% | 152.6%
Net Income
75.2% | 86.7%
Free Cash Flow
130.9%
Margin (TTM | estimate)
Gross
84.6%
EBITDA
7.8% | 18.4%
EBIT
3.7%
Net
-5.9% | -2.5%
Free Cash Flow
3.8%
More
EPS
$-0.1
FCF per Share
$0.1
Short interest
9.7%
Employees
394
Rev per Employee
$520.0k
Show more

Is Xeris Biopharma Holdings a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Xeris Biopharma Holdings Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Xeris Biopharma Holdings forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Xeris Biopharma Holdings forecast:

Buy
83%
Hold
17%

Financial data from Xeris Biopharma Holdings

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
266 266
42% 42%
100%
- Direct Costs 41 41
18% 18%
15%
225 225
48% 48%
85%
- Selling and Administrative Expenses 175 175
9% 9%
66%
- Research and Development Expense 29 29
14% 14%
11%
21 21
160% 160%
8%
- Depreciation and Amortization 11 11
0% 0%
4%
EBIT (Operating Income) EBIT 9.80 9.80
122% 122%
4%
Net Profit -16 -16
75% 75%
-6%

In millions USD.

Don't miss a Thing! We will send you all news about Xeris Biopharma Holdings directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xeris Biopharma Holdings Stock News

Neutral
Business Wire
25 days ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.'s U.S. pa...
Neutral
Seeking Alpha
about 2 months ago
Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Allison Wey - Senior Vice President of Investor Relations & Corporate Communications John Shannon - CEO & Director Steven Pieper - Chief Financial Officer Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, ...
Neutral
Business Wire
about 2 months ago
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter ended September 30, 2025. “We delivered another record-breaking quarter, driven by increased patient demand...
More Xeris Biopharma Holdings News

Company Profile

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol and XeriJect formulation technologies. Its products include Gvoke Pre-Filled Syringe and Gvoke HypoPen. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Chicago, IL.

Head office United States
CEO John Shannon
Employees 394
Founded 2005
Website www.xerispharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today